EEG–mapping differences between narcolepsy patients and controls and subsequent double–blind, placebo–controlled studies with modafinil

AbstractThe aim of the present study was to investigate the role of EEG mapping as an objective and quantitative measure of vigilance in untreated and modafinil–treated narcoleptics, and compare it with the conventional neurophysiological method of the Multiple Sleep Latency Test (MSLT) and the subjective Epworth Sleepiness Scale (ESS). In 16 drug–free narcoleptics and 16 normal controls a baseline 3–min vigilance–controlled EEG (V–EEG) and a 4–min resting EEG (R–EEG) were recorded during midmorning hours. Thereafter, in a double–blind, placebo–controlled crossover design, patients were treated with a 3–week fixed titration of modafinil (200, 300, 400 mg) and placebo. EEG–mapping, MSLT and ESS measures were obtained before and at the end of the third week of therapy. Statistical overall analysis by means of the omnibus significance test demonstrated significant EEG differences between untreated patients and controls in the resting condition only (R–EEG). Subsequent univariate analysis revealed an increase in absolute and relative theta power, a decrease in alpha–2 and beta power as well as a slowing of the dominant frequency and the centroids of the alpha, beta and total power spectrum and thus objectified a vigilance decrement in narcolepsy. Modafinil 400 mg/d significantly improved vigilance as compared with placebo (p ≤ 0.01), inducing changes opposite to the aforementioned baseline differences (key–lock principle). The MSLT and the ESS also improved under modafinil as compared with placebo, but changes were less consistent. Spearman rank correlations revealed the highest correlations between EEG mapping and the ESS, followed by those between EEG mapping and the MSLT, while the lowest correlation was found between the MSLT and the ESS. In conclusion, EEG mapping is a valuable instrument for measuring vigilance decrements in narcolepsy and their improvement under psychostimulant treatment.

[1]  C. Stampi,et al.  A new quantitative method for assessing sleepiness: The alpha attenuation test , 1995 .

[2]  R. Chervin,et al.  Comparison of the results of the Epworth Sleepiness Scale and the Multiple Sleep Latency Test. , 1997, Journal of psychosomatic research.

[3]  R D Pascual-Marqui,et al.  EEG topography and tomography in diagnosis and treatment of mental disorders: evidence for a key-lock principle. , 2002, Methods and findings in experimental and clinical pharmacology.

[4]  M. Billiard,et al.  Effets du modafinil (300 mg) sur le sommeil, la somnolence et la vigilance du narcoleptique , 1993, Neurophysiologie Clinique/Clinical Neurophysiology.

[5]  J. Montplaisir,et al.  Effects of modafinil on symptomatology of human narcolepsy. , 1993, Clinical neuropharmacology.

[6]  B. Saletu.  Visualizing the Living Human Brain. The Techniques and Promise of EEG and Event-Related Potentials Mapping , 1998 .

[7]  M. Buchsbaum,et al.  Topographic EEG changes with benzodiazepine administration in generalized anxiety disorder , 1985, Biological Psychiatry.

[8]  A. Rechtschaffen.  A manual of standardized terminology, techniques and scoring system for sleep of human subjects , 1968 .

[9]  M. Carskadon,et al.  Guidelines for the multiple sleep latency test (MSLT): a standard measure of sleepiness. , 1986, Sleep.

[10]  C. Alloway,et al.  The alpha attenuation test: assessing excessive daytime sleepiness in narcolepsy-cataplexy. , 1997, Sleep.

[11]  H. Moldofsky,et al.  Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy , 1997, Neurology.

[12]  A Gevins,et al.  High resolution EEG: 124-channel recording, spatial deblurring and MRI integration methods. , 1994, Electroencephalography and clinical neurophysiology.

[13]  M. Hirshkowitz,et al.  Sleep latency on the maintenance of wakefulness test (MWT) for 530 patients with narcolepsy while free of psychoactive drugs. , 1998, Electroencephalography and clinical neurophysiology.

[14]  Edward M. Cross,et al.  Use of the Binomial Theorem in Interpreting Results of Multiple Tests of Significance , 1982 .

[15]  P. Anderer,et al.  Differential effects of the new central adrenergic agonist modafinil and d-amphetamine on sleep and early morning behaviour in elderlies. , 1989, Arzneimittel-Forschung.

[16]  P. Anderer,et al.  EEG-brain mapping in schizophrenics with predominantly positive and negative symptoms Comparative studies with remoxipride/haloperidol , 1990, European Neuropsychopharmacology.

[17]  S. Himanen,et al.  Limitations of Rechtschaffen and Kales. , 2000, Sleep medicine reviews.

[18]  Thomas Dierks,et al.  Atlas of Brain Mapping: Topographic Mapping of Eeg and Evoked Potentials , 1991 .

[19]  R B Sangal,et al.  Longer Auditory and Visual P300 Latencies in Patients with Narcolepsy , 1999, Clinical EEG.

[20]  E. John,et al.  Neurometrics: computer-assisted differential diagnosis of brain dysfunctions. , 1988, Science.

[21]  M. Johns,et al.  A new method for measuring daytime sleepiness: the Epworth sleepiness scale. , 1991, Sleep.

[22]  M. Mitler,et al.  Maintenance of wakefulness test: a polysomnographic technique for evaluation treatment efficacy in patients with excessive somnolence. , 1982, Electroencephalography and clinical neurophysiology.

[23]  B. Saletu,et al.  On the treatment of the alcoholic organic brain syndrome with an alpha-adrenergic agonist modafinil: double-blind, placebo-controlled clinical, psychometric and neurophysiological studies , 1990, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[24]  Raymond Cluydts,et al.  Daytime sleepiness and its evaluation. , 2002, Sleep medicine reviews.

[25]  M. Thorpy,et al.  Current concepts in the etiology, diagnosis and treatment of narcolepsy. , 2001, Sleep medicine.

[26]  Y. Honda.  Clinical Features of Narcolepsy: Japanese Experiences , 1988 .

[27]  H. Head.  THE CONCEPTION OF NERVOUS AND MENTAL ENERGY1 (II) , 1923 .

[28]  M. Jouvet,et al.  Successful treatment of idiopathic hypersomnia and narcolepsy with modafinil , 1988, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[29]  E. Wolpert.  A Manual of Standardized Terminology, Techniques and Scoring System for Sleep Stages of Human Subjects. , 1969 .

[30]  A. Besset,et al.  Modafinil: a double-blind multicentric study. , 1994, Sleep.

[31]  Prof. Dr. Konrad Maurer,et al.  Atlas of Brain Mapping , 1991, Springer Berlin Heidelberg.

[32]  H. Semlitsch,et al.  Visualizing central effects of S-adenosyl-L-methionine (SAMe), a natural molecule with antidepressant properties, by pharmaco-EEG mapping. , 2002, The international journal of neuropsychopharmacology.

[33]  M Partinen,et al.  Epidemiology of narcolepsy. , 1994, Sleep.

[34]  F. Duffy,et al.  Significance probability mapping: an aid in the topographic analysis of brain electrical activity. , 1981, Electroencephalography and clinical neurophysiology.

[35]  Bernd Saletu,et al.  Artifact processing in topographic mapping of electroencephalographie activity in neuropsychopharmacology , 1992, Psychiatry Research: Neuroimaging.

[36]  G. Mayer,et al.  Modafinil in diurnal sleepiness. A study of 123 patients. , 1994, Sleep.

[37]  R D Pascual-Marqui,et al.  Classification and evaluation of the pharmacodynamics of psychotropic drugs by single-lead pharmaco-EEG, EEG mapping and tomography (LORETA). , 2002, Methods and findings in experimental and clinical pharmacology.

[38]  D. Bente.  Vigilanz: Psychophysiologische Aspekte , 1977 .

[39]  Christian Guilleminault,et al.  Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy , 2000, Neurology.

[40]  E. Mignot,et al.  Narcolepsy:Clinical Features, New Pathophysiologic Insights, and Future Perspectives , 2001, Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society.

[41]  P. Anderer,et al.  Differential effects of a new central adrenergic agonist--modafinil--and D-amphetamine on sleep and early morning behaviour in young healthy volunteers. , 1989, International journal of clinical pharmacology research.

[42]  D. Lehmann,et al.  Functional imaging with low-resolution brain electromagnetic tomography (LORETA): a review. , 2002, Methods and findings in experimental and clinical pharmacology.

[43]  P. Anderer,et al.  EEG mapping in patients with restless legs syndrome as compared with normal controls , 2002, Psychiatry Research: Neuroimaging.

[44]  B. Saletu,et al.  Pharmaco-EEG, psychometric and plasma level studies with two novel alpha-adrenergic stimulants CRL 40476 and 40028 (adrafinil) in elderlies. , 1986 .

[45]  B. Saletu.  EEG Brain Mapping in Diagnostic and Therapeutic Assessment of Dementia , 1991, Alzheimer disease and associated disorders.

[46]  B. Saletu,et al.  Memory Dysfunction and Vigilance: Neurophysiological and Psychopharmacological Aspects , 1985, Annals of the New York Academy of Sciences.

[47]  D. Fry,et al.  Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy , 1998, Annals of neurology.

[48]  M. Carskadon,et al.  Excessive daytime sleepiness in man: multiple sleep latency measurement in narcoleptic and control subjects. , 1978, Electroencephalography and clinical neurophysiology.

[49]  B Saletu,et al.  Topographic brain mapping of EEG in neuropsychopharmacology--Part I. Methodological aspects. , 1987, Methods and findings in experimental and clinical pharmacology.

[50]  D. Greenblatt,et al.  The International Classification of Sleep Disorders , 1992 .

[51]  T. Gasser,et al.  Transformations towards the normal distribution of broad band spectral parameters of the EEG. , 1982, Electroencephalography and clinical neurophysiology.

[52]  C. Guilleminault,et al.  Long-term efficacy and safety of modafinil (PROVIGIL((R))) for the treatment of excessive daytime sleepiness associated with narcolepsy. , 2000, Sleep medicine.

[53]  Hill,et al.  A randomized trial of the long-term, continued efficacy and safety of modafinil in narcolepsy. , 2000, Sleep medicine.